Vaxcyte — Financial Results
Net Loss Surged 65% as the Company Accelerates Toward Potential Product Launch
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Loss | $402.3M | $463.9M | $766.6M |
| R&D Expenses | $332.3M | $476.6M | $794.3M |
| Cash & Investments | — | — | $2,442.6M |
Vaxcyte has no products on the market and no revenue from sales — every dollar spent comes from money raised by issuing shares to investors. The net loss jumped by $302.7 million in 2025, driven almost entirely by a 67% surge in research and development (R&D) expenses, as the company ramps up manufacturing and clinical trials ahead of a potential product launch. Cash reserves of $2.4 billion are described as sufficient for at least 12 months of operations.
Manufacturing Costs More Than Doubled as the Company Prepares for Commercial Scale
| Cost Category | 2024 | 2025 | Change |
|---|---|---|---|
| Product Manufacturing | $173.3M | $403.2M | +133% |
| Clinical Trials | $66.5M | $83.8M | +26% |
| Personnel (R&D) | $127.1M | $193.6M | +52% |
The single biggest driver of rising costs was product manufacturing, which more than doubled year-over-year. This reflects Vaxcyte building up drug supply not just for clinical trials, but in anticipation of a potential commercial launch. The company has locked in long-term manufacturing deals with Lonza (through 2038, based in Switzerland) and Thermo Fisher (a 15-year deal in North Carolina worth up to $1 billion), signalling serious commercial intent.
VAX-31 Enters Phase 3 With FDA Breakthrough Status and Three Simultaneous Trials
VAX-31, the company's lead vaccine candidate targeting 31 strains of pneumococcal (pneumonia-causing) bacteria, received Breakthrough Therapy Designation (BTD) from the FDA — a status reserved for drugs that may offer meaningful improvements over existing treatments. Three Phase 3 trials (OPUS-1, OPUS-2, and OPUS-3) are now underway across roughly 105 U.S. sites, testing VAX-31 in adults aged 50 and older in different scenarios. Topline data from the pivotal OPUS-1 trial is expected in the fourth quarter of 2026, with the other two reading out in the first half of 2027. A BLA (Biologics License Application) — the formal request for FDA approval to sell the product — is planned shortly after the last study completes.
Positive Phase 2 Results in Infants Keep the Pediatric Pipeline on Track
Both VAX-24 and VAX-31 showed encouraging Phase 2 results in infants, with safety profiles similar to existing approved vaccines and strong immune responses across multiple dose levels. Enrollment in the VAX-31 infant study (900 participants) was completed in January 2026, with topline data expected by mid-2027. Pending those results, the company plans to advance directly into a Phase 3 infant trial. The pediatric market represents an additional commercial opportunity beyond the adult indication already in Phase 3.
A $632.5 Million Share Offering Keeps the Company Well Funded
In February 2026 — just after the fiscal year ended — Vaxcyte raised $632.5 million by selling 12.65 million new shares at $50.00 each. Combined with the $2.4 billion already on hand at year-end, the company has substantial capital to fund its expanding clinical program. However, the company is explicit that it will need to raise additional capital beyond this to fully commercialize its vaccines, meaning further dilution (reduction in existing shareholders' ownership percentage) is likely.